Modified, weekly dosing with docetaxel and cisplatin as first-line therapy in advanced non-small cell lung cancer

Shih Chuan Hsiao, Wu-Chou Su

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background. Platinum-based combination chemotherapy regimens provide modest improvement in both survival and quality of life for patients with non-small cell lung cancers and docetaxel is the first agent approved for both first- and second-line treatment in patients with advanced disease. However, the regimens are associated with adverse effects. Methods. We used a modified, shortened regimen with only 2 consecutive weekly infusions of docetaxel followed by rest for 1 week, and evaluated the efficacy and toxicity profiles in patients undergoing treatment for non-small cell lung cancers. Thirty-five patients (19 men, 16 women) with advanced non-small cell lung cancers received docetaxel (35 mg/m2 i.v. infusion on days 1 and 8) with cisplatin (60 mg/m 2 i.v. infusion on day 8) in 126 cycles. Results. Two of the 35 patients achieved complete response (5.7%), while 16 patients achieved partial response (45.7%). The overall response rate was 51.4% and median overall survival was 10.6 months. The toxicities were mild; the most common grades 3 and 4 toxicities were anaemia (5.6%), neutropenia (4.8%) and vomiting (5.6%). Other grades 3 and 4 non-haematological toxicities included diarrhoea (3.2%), neurotoxicity (0.8%), asthenia (0.8%) and phlebitis (0.8%). Conclusion. Combination chemotherapy with cisplatin and 2 consecutive weekly infusions of docetaxel can be considered an active and well-tolerated regimen with a good response rate and less toxicity for patients with advanced non-small cell lung cancers.

Original languageEnglish
Pages (from-to)67-69
Number of pages3
JournalNational Medical Journal of India
Volume22
Issue number2
Publication statusPublished - 2009 Mar

Fingerprint

docetaxel
Non-Small Cell Lung Carcinoma
Cisplatin
Combination Drug Therapy
Therapeutics
Phlebitis
Asthenia
Survival
Neutropenia
Platinum
Vomiting
Anemia
Diarrhea

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

@article{0b525d61b91f4b1aaf3a47a704d87568,
title = "Modified, weekly dosing with docetaxel and cisplatin as first-line therapy in advanced non-small cell lung cancer",
abstract = "Background. Platinum-based combination chemotherapy regimens provide modest improvement in both survival and quality of life for patients with non-small cell lung cancers and docetaxel is the first agent approved for both first- and second-line treatment in patients with advanced disease. However, the regimens are associated with adverse effects. Methods. We used a modified, shortened regimen with only 2 consecutive weekly infusions of docetaxel followed by rest for 1 week, and evaluated the efficacy and toxicity profiles in patients undergoing treatment for non-small cell lung cancers. Thirty-five patients (19 men, 16 women) with advanced non-small cell lung cancers received docetaxel (35 mg/m2 i.v. infusion on days 1 and 8) with cisplatin (60 mg/m 2 i.v. infusion on day 8) in 126 cycles. Results. Two of the 35 patients achieved complete response (5.7{\%}), while 16 patients achieved partial response (45.7{\%}). The overall response rate was 51.4{\%} and median overall survival was 10.6 months. The toxicities were mild; the most common grades 3 and 4 toxicities were anaemia (5.6{\%}), neutropenia (4.8{\%}) and vomiting (5.6{\%}). Other grades 3 and 4 non-haematological toxicities included diarrhoea (3.2{\%}), neurotoxicity (0.8{\%}), asthenia (0.8{\%}) and phlebitis (0.8{\%}). Conclusion. Combination chemotherapy with cisplatin and 2 consecutive weekly infusions of docetaxel can be considered an active and well-tolerated regimen with a good response rate and less toxicity for patients with advanced non-small cell lung cancers.",
author = "Hsiao, {Shih Chuan} and Wu-Chou Su",
year = "2009",
month = "3",
language = "English",
volume = "22",
pages = "67--69",
journal = "National Medical Journal of India",
issn = "0970-258X",
publisher = "All India Institute of Medical Sciences",
number = "2",

}

Modified, weekly dosing with docetaxel and cisplatin as first-line therapy in advanced non-small cell lung cancer. / Hsiao, Shih Chuan; Su, Wu-Chou.

In: National Medical Journal of India, Vol. 22, No. 2, 03.2009, p. 67-69.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Modified, weekly dosing with docetaxel and cisplatin as first-line therapy in advanced non-small cell lung cancer

AU - Hsiao, Shih Chuan

AU - Su, Wu-Chou

PY - 2009/3

Y1 - 2009/3

N2 - Background. Platinum-based combination chemotherapy regimens provide modest improvement in both survival and quality of life for patients with non-small cell lung cancers and docetaxel is the first agent approved for both first- and second-line treatment in patients with advanced disease. However, the regimens are associated with adverse effects. Methods. We used a modified, shortened regimen with only 2 consecutive weekly infusions of docetaxel followed by rest for 1 week, and evaluated the efficacy and toxicity profiles in patients undergoing treatment for non-small cell lung cancers. Thirty-five patients (19 men, 16 women) with advanced non-small cell lung cancers received docetaxel (35 mg/m2 i.v. infusion on days 1 and 8) with cisplatin (60 mg/m 2 i.v. infusion on day 8) in 126 cycles. Results. Two of the 35 patients achieved complete response (5.7%), while 16 patients achieved partial response (45.7%). The overall response rate was 51.4% and median overall survival was 10.6 months. The toxicities were mild; the most common grades 3 and 4 toxicities were anaemia (5.6%), neutropenia (4.8%) and vomiting (5.6%). Other grades 3 and 4 non-haematological toxicities included diarrhoea (3.2%), neurotoxicity (0.8%), asthenia (0.8%) and phlebitis (0.8%). Conclusion. Combination chemotherapy with cisplatin and 2 consecutive weekly infusions of docetaxel can be considered an active and well-tolerated regimen with a good response rate and less toxicity for patients with advanced non-small cell lung cancers.

AB - Background. Platinum-based combination chemotherapy regimens provide modest improvement in both survival and quality of life for patients with non-small cell lung cancers and docetaxel is the first agent approved for both first- and second-line treatment in patients with advanced disease. However, the regimens are associated with adverse effects. Methods. We used a modified, shortened regimen with only 2 consecutive weekly infusions of docetaxel followed by rest for 1 week, and evaluated the efficacy and toxicity profiles in patients undergoing treatment for non-small cell lung cancers. Thirty-five patients (19 men, 16 women) with advanced non-small cell lung cancers received docetaxel (35 mg/m2 i.v. infusion on days 1 and 8) with cisplatin (60 mg/m 2 i.v. infusion on day 8) in 126 cycles. Results. Two of the 35 patients achieved complete response (5.7%), while 16 patients achieved partial response (45.7%). The overall response rate was 51.4% and median overall survival was 10.6 months. The toxicities were mild; the most common grades 3 and 4 toxicities were anaemia (5.6%), neutropenia (4.8%) and vomiting (5.6%). Other grades 3 and 4 non-haematological toxicities included diarrhoea (3.2%), neurotoxicity (0.8%), asthenia (0.8%) and phlebitis (0.8%). Conclusion. Combination chemotherapy with cisplatin and 2 consecutive weekly infusions of docetaxel can be considered an active and well-tolerated regimen with a good response rate and less toxicity for patients with advanced non-small cell lung cancers.

UR - http://www.scopus.com/inward/record.url?scp=69249200572&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69249200572&partnerID=8YFLogxK

M3 - Article

VL - 22

SP - 67

EP - 69

JO - National Medical Journal of India

JF - National Medical Journal of India

SN - 0970-258X

IS - 2

ER -